Sitemap

Ana Govedarica, Roche Serbia General Manager & SSCC Board Member

New Medicines Available Quicker Than Ever

Portonovi

Endless Summer Adventures And Relaxation On The Adriatic Coast

Portonovi Resort, a luxurious and unique destination...

Farewell Party In Honor Of Ambassador Of Belgium Koenraad Adam

Belgian Serbian Business Association hosted a Belgian...

AHK Sommerfest Held

After almost three years, AHK (German-Serbian Chamber...

International Day Of Yoga Marked At Kalemegdan

Ambassador of India to Serbia Sanjiv Kohli...

UK: Lowest Car Sales Since 1996

Gathering economic headwinds are stoking fears of a recession after car sales dropped to the lowest level since 1996. UK...

In The New Report On Serbia GRECO Calls For Further Measures To Prevent Corruption

In a new report on Serbia, the Council of Europe’s Group of States against Corruption (GRECO) calls for further measures to...

China: Ready To Promote Global Development

The Forum on Global Development was held in Beijing, and on that occasion the President of the People's Republic...

Serbia And Hungary Sign Agreement On Border Control

The Agreement between the governments of Serbia and Hungary regulating border control in road, rail and water transport was...

Reception On The Occasion Of 140 Years Of Friendly Relations Between Japan And Serbia

Ambassador of Japan in Serbia H.E. Katsumata Takahiko hosted a reception in his residence to mark the 140th anniversary...

Roche applies a flexible model through which, in cooperation with local health systems, prices are determined on the basis of the budgets of health funds and the effects they have on individuals

Exciting things are happening in medicine and healthcare is improving faster in this decade than ever before, especially in the field of oncology. Scientists have good news every day, giving patients new hope and possibilities.

However, when they complete their part of the job, it is equally important whether and in what way new therapies will be available to patients, says Roche Serbia General Manager Ana Govedarica.

What has led to such rapid progress in medicine?

-The concept of treatment is essentially changing. Molecular biology launched a revolution in the way we prevent, diagnose and treat diseases: personalised healthcare. As scientists have begun to understand, target, and diagnose illnesses on a molecular level, the approach to treatment has changed fundamentally. Cancer, for instance, is not one disease, but the result of innumerable genetic mutations. This evolving understanding of the disease is making it possible to create targeted medicines for groups of people with the drivers of the same disease, making a difference in the lives of many people with serious illnesses.

In the era of digital technology, we will increasingly be able to tailor medical treatment to the needs of individuals and small groups of patients, because we can review more information about how diseases manifest themselves and how patients experience them day-to-day.

At Roche, we are taking personalised healthcare toward a future where treatments are targeted to an individual’s needs and unique genetic profile. We look at this opportunity through the perspective of the purpose of providing a lasting contribution to patients, and as a company that has repeatedly proven, it can reinvent medical textbooks in every generation.

Roche has developed a unique footprint as a partner across the entire spectrum of modern healthcare, deeper and broader than most companies, by focusing on innovative diagnostics and pharmaceuticals under one roof.

Are these modern achievements available to patients around the world?

– One of the main challenges is to provide therapies in countries with completely different levels of economic development and possibilities. Patients in highly developed countries usually have more choices concerning therapies than in less developed countries. Roche, in order to expand the availability of its therapies, applies a flexible model through which, in cooperation with local healthcare systems, prices are defined on the basis of several different factors: from the budgets of healthcare funds, institutions and individuals, to the measurement of the effect of the drug within the therapy given to the patient.

At Roche, we are taking personalised healthcare toward a future where treatments are targeted to an individual’s needs and unique genetic profile

This system is fair, and patients and healthcare systems pay for the realistic effect of the drug. At the same time, the richest countries have agreed to Roche’s initiative to abandon the “same global price” principle, in order to make treatments available to patients in less-developed countries.

What is the situation in Serbia?

– Pressure on healthcare systems around the world is constantly increasing, primarily because people live longer; the population is getting older and their healthcare needs are increasing. On the other hand, it is proven that modern therapies improve the quality and length of the life of patients and in the long run reduce community costs through the faster recovery of patients and by increasing the working capacity of the population.

In this “juggling”, it is important that all participants in the healthcare system see the bigger picture and measure the effects of each decision: when and where to make savings, and where to invest to make the system more efficient. It is clear that countries with an economy like Serbia’s have rather a difficult task in providing patients with the most effective treatment.

The several-year delay in placing innovative medicines on the so-called reimbursement list paid by the healthcare fund, on the one hand, and the rapid progress of the development of new therapies, on the other, are the main reasons why Serbia is still lagging behind in some therapeutic areas compared to the world and the region.

Over the past three years, the state has made visible progress regarding this issue by introducing managed entry agreements and allowing the use of certain innovative drugs, but also through regular payments of obligations to suppliers and consequent stability in the supply of medicines. Still, if we look at the figures, we have to conclude that there is still a lot to be improved.

About 750 million euros is spent on medicines in Serbia, 400 million of which is covered by the state. Only 140 million is allocated for innovative drugs, 50 million of which is for oncology. Increasing the budget for innovative drugs to at least 200-250 million euros is a smart investment that returns a better efficacy of the healthcare system and improves patients’ lives.

Over the past three years, Serbia has made visible progress regarding this issue by introducing managed entry agreements and allowing the use of certain innovative drugs, but also through regular payments of obligations to suppliers and consequent stability in the supply of medicines

Is Serbia moving in the right direction in terms of improving healthcare?

– Pharmaceutical companies and state representatives have an open dialogue concerning specific actions to be taken to create a significant shift regarding the availability of the most advanced therapies in Serbia in the near future and to reach the coverage of the other countries of the region.

Roche has demonstrated an understanding for patients’ needs, as well as the economic limits of the state, and we are continually making great efforts to provide drugs under significantly more favourable conditions than in highly developed countries. At the same time, we are ready to partner with relevant stakeholders in order to support the modernisation and digitisation of Serbian hospitals, relevant patient registries, online CME projects etc.

In your opinion, what is of key importance regarding the wider availability of medicines in the years ahead?

– It is important that the pharmaceutical industry has an open dialogue and develops a partnership with the healthcare system. The mutual understanding, new models of financing and procurement of innovative drugs, stability and predictability could result in improvement regarding access to new therapies in the coming years. Investing in healthcare must not be reduced and an increase in the GDP should be accompanied by increased healthcare investments that will return much higher value to the society, as has been proven many times worldwide.

Related Articles

Swiss Cooperation Program For Serbia 2022-25 Introduced

Support of Switzerland for Serbia in the European integration process, contributing to sustainable inclusive growth and encouraging democratic processes was announced at a ceremony...

Swiss-Serbian Chamber of Commerce General Assembly 2022

Swiss-Serbian Chamber of Commerce online General Assembly was held on February 24, 2022 at 12h00. On this occasion, fours SSCC members were elected: – Mrs....

Aleksandra Vidaković Lazić, Country Medical Director, Roche

Radical Changes Are Reshaping Healthcare

Innovations in the health sector are made possible by technologies that range from blockchain and artificial intelligence to big data analytics and advanced sensors The...

The Foreign Investors Council Held Its Regular Annual Assembly

The Foreign Investors Council (FIC) held the regular annual session of the Assembly, electing the new Board of Directors, adopting the Annual and Financial...

Digital Transformation Of Healthcare Ecosystem

Digital Health Strategy 2022-26 and Action Plan 2022-23 of the Republic of Serbia are now being finalized with the aim of ensuring a healthier...

Ana Govedarica, FIC Vice President And Spokesperson (Roche Serbia General Manager)

FIC Experience & Knowhow At The Serbia’s Disposal

Serbia has good foundations for the digitalisation of health and could progress very quickly and provide high-quality services that meet the level of the...

Radomir Cerović, President Of The FIC Pharmaceutical Industry Committee (Roche d.o.o.)

Digitalisation Leads To Better Quality Healthcare Protection

The digitalisation of healthcare, which has been announced by the Government of Serbia, represents an important step towards the all-encompassing recovery of the state...

Comment

New Ways To Promote Good

It is time to reflect on the past 30 years of the bilateral cooperation programme and seek new paths of collaboration. Switzerland’s longstanding commitment...